In vivo immunosuppressive activity of some cyclolignans

Bioorganic and Medicinal Chemistry Letters

Volumn 7, Issue 21, 1997, Pages 2781-2786

  Gordaliza, Marina ^a   Castro, M Angeles ^a   Miguel del Corral, José M ^a   López Vázquez, M Luisa ^a   San Feliciano, Arturo ^a   Faircloth, Glynn T ^b  

^a UNIVERSITY OF SALAMANCA   (Spain)

^b PharmaMar USA Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOSUPPRESSIVE AGENT; LIGNAN DERIVATIVE; PODOPHYLLOTOXIN DERIVATIVE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; CYTOTOXICITY; DRUG ACTIVITY; DRUG SYNTHESIS; GRAFT SURVIVAL; GRAFT VERSUS HOST REACTION; IMMUNOCOMPETENT CELL; NONHUMAN; SKIN TRANSPLANTATION; SPLENOMEGALY;

EID: 0030785273     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0960-894X(97)10072-5     Document Type: Article

References (30)

1. Borel, J. F. In Cyclosporin A; Borel, J. F., Ed.; Elsevier: Amsterdam, 1982; pp 5-17.
2. (a) Takana, H.; Kuroda, A.; Marusawa, H.; Hatanaka, H.; Hashimoto, M.; Kino, T.; Goto, T.; Taga, T. J. Am. Chem. Soc. 1987, 109, 5031.
3. (b) Kino, T.; Hatanaka, H.; Hashimoto, M.; Nishiyama, M.; Goto, T.; Okuhara, M.; Kohsaka, M.; Aoki, H.; Imanaka, H. J. Antibiot. 1987, 40, 1249.
4. Wong, S. In Kirk-Othmer Encyclopedia of Chemical Technology; Kroschwitz, J.I.; Howe-Grant M. Eds.; John Wiley & Sons: New York, 1995; vol. 14, p.64.
5. (a) Fujita, T.; Inoue, K.; Yamamoto, S.; Ikumoto, T.; Sasaki, S.; Toyama, R.; Chiba, K.; Hoshino, Y.; Okumoto, T. J. Antibiot. 1994, 47, 208.
6. (b) Fujita, T.; Hirose, R.; Yoneta, M.; Sasaki, S.; Inoue, K.; Kiuchi, M.; Hirase, S.; Chiba, K.; Sakamoto, H.; Arita, M. J. Med. Chem. 1996, 39, 4451.
7. (a) Steinmuller, D. R. Cleveland Clin. J. Med. 1989, 56, 89.
8. (b) Heering, P.; Schadewaldt, P.; Bach, D.; Grabensee, B. Clin. Invest. 1993, 71, 1010.
9. Feutren, G. M.; Hatsch, M. J. N. Engl. J. Med. 1992, 326, 1654.
10. Textor, S. C.; Canzanello, V. J.; Taler, S. J.; Wilson, D. J.; Schwartz, L. L.; Augustine, J. E.; Raymer, J. M.; Romero, J. C.; Weisner, R. H.; Krom, R. A. Mayo Clin. Proc. 1994, 69, 1182.
11. Wilson, J. R.; Eidelman, B.; Abu-Elmagd, K.; Fung, J.; Todo, S.; Van Thiel, D.; Starzl, T. Neurology 1992, 42 (Suppl. 3), 247S.
12. Thomason, J. M.; Seymour, R. A.; Ellis, J. Ren. fail. 1994, 16, 731.
13. Burren, C. P.; Jones, C. L.; Francis, D. M.; Powell, H. R.; Walker, R. G. Aust. N. Z. J. Med. 1995, 25, 122.
14. Thiru, S. In Cyclosporin: Mode of Action and Clinical Applications; Thompson, A. W., Ed.; Kluwer Academic Publisers: Dordrecht, 1989; pp 324-364.
15. Morris, R. E. J. Heart Lung Transplant. 1993, 12, 3275.
16. Gordaliza, M.; Faircloth, G. T.; Castro, M. A.; Miguel del Corral, J. M.; López-Vázquez, M. L.; San Feliciano, A. J. Med. Chem. 1996, 39, 2865.
17. (a) Gordaliza, M.; Miguel del Corral, J. M.; Castro, M. A.; López-Vázquez, M. L.; San Feliciano, A.; García-Grávalos, M. D.; Carpy, A. Bioorg. Med. Chem. 1995, 3, 1203.
18. (b) Gordaliza, M.; Castro, M. A.; García-Grávalos, M. D.; Ruiz, P.; Miguel del Corral, J. M.; San Feliciano, A. Arch. Pharm. (Weinheim) 1994, 327, 175.
19. (c) San Feliciano A.; Gordaliza, M.; Miguel del Corral, J. M.; Castro, M. A.; GarcíaGrávalos, M. D.; Ruiz-Lázaro, P. Planta Med. 1993, 59, 246.
20. (d) Beard, A. R.; Drew, M. G. B.; Hilgard, P.; Hudson, B. D.; Mann, J.; Neidle, S.; Wong, L. F. T. Anti-Cancer Drug Desing, 1987, 2, 247.
21. (a) Biogenetic numbering according to Moss G. P. (1987, Paper to the Biochemistry Commitee of the International Union of Pure & Applied Chemistry) is used in this paper.
22. (b) Ayres, D. C.; Loike, J. D. Lignons. Chemical, Biological and Clinical Properties. Cambridge University Press: Cambridge, UK, 1990.
23. Ito, C.; Matsui, T.; Wu, T. S.; Furukawa, H. Chem Pharm. Bull. 1992, 40, 1318.
24. Buchardt, O.; Jensen, R. B.; Hansen, H. F.; Nielsen, P. E.; Andersen, D.; Chinoin, I. J. Pharm. Sci. 1986, 75, 1076.
25. Wang, D.-Q.; Hu, H.; Chen, H.-X.; Cheng, Y.-C.; Lee, K.-H. J. Med. Chem. 1992, 35, 871.
26. Terada, T.; Fujimoto, K.; Nomura, M.; Yamashita, J.-I.; Kobunai, T.; Takeda, S.; Wierzba, K.; Yamada, Y.; Yamaguchi, H. Chem. Pharm. Bull. 1992, 40, 2720.
27. Teitel, S.; O'Brien, J.; Brossi, A. J. Org. Chem. 1972, 37, 3368.
28. Schreier, E. Helv. Chem. Acta, 1964, 47, 1529.
29. Simonsen, M. Progr. Allergy, 1962, 6, 349-467.
30. d) mice. A liquid bandage was applied to the grafted area of the recipient animal by using an aerosol form of a Collodion (containing no clove extracts of other fragrances)/isopropanol solution. On Dl (> 16 hours), groups of individually caged animals (5/group) received an i.p. injection per diem of an active dose of test compounds, as previously determined in the GVHR, for as long as the graft survived up to 30 days. Grafts that slough-off on or before D3 post transplantation were considered 'no takes'. Normal graft rejection in control animals occured between day 5-6 post transplantation. Beyond D6, evaluation of the grafted skin was graded daily for the following characteristics: erythema, crusting, purulent discharges, sensation of the grafted skin and status of the hair (occuring in prolonged graft survival studies). 'No takes', control animals post D6 and moribund animals were sacrificed. Experimental animals were sacrificed on the day of graft rejection or D30, whichever came first.